Showing results (81-90 of 113) with videos related to

Sort By:
Pageof 12
Blood|October 22, 2009
Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutationFranck E Nicolini, Michael J Mauro, Giovanni Martinelli, et al.
Blood|December 10, 2016
Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI studyDelphine Rea, Franck E Nicolini, Michel Tulliez, et al.
Leukemia|May 23, 2020
Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemiaRahul Kumar, Raquel S Pereira, Costanza Zanetti, et al.
Annals of Internal Medicine|February 21, 2018
Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label StudyFrançois-Xavier Mahon, Carla Boquimpani, Dong-Wook Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2013
Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable diseasePhilippe Rousselot, Aude Charbonnier, Pascale Cony-Makhoul, et al.
The Lancet. Haematology|December 22, 2015
Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 studyFranck E Nicolini, Gabriel Etienne, Viviane Dubruille, et al.
British Journal of Haematology|November 7, 2024
Clinical outcomes in patients in any phase of CML treated with ponatinib in France-Data from the TOPASE observational studyF Huguet, A Guerci-Bresler, G Roth-Guepin, et al.
The Lancet. Haematology|May 1, 2019
Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based studyAytug Kizilors, Elena Crisà, Nicholas Lea, et al.
Blood|December 14, 2011
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)Hagop M Kantarjian, Neil P Shah, Jorge E Cortes, et al.
Blood|November 26, 2015
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patientsMichael W Deininger, J Graeme Hodgson, Neil P Shah, et al.
Pageof 12